{"data":[{"Ravimiameti referentsnumber":"14-060","EU CT number":"2023-504034-22-00","Uuringu sponsor":"F. Hoffmann-La Roche AG","Protokolli number":"BO25323","Uuringu nimetus":"A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions","Eriala":"onkoloogia","Esitamise kuupäev":"11/6/14","Loa saamise kuupäev":"11/12/14"},{"Ravimiameti referentsnumber":"15-041","EU CT number":"2023-509137-39-00","Uuringu sponsor":"Merck Sharp & Dohme LLC","Protokolli number":"MK-3475-091","Uuringu nimetus":"A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091","Eriala":"onkoloogia","Esitamise kuupäev":"8/3/15","Loa saamise kuupäev":"9/1/15"},{"Ravimiameti referentsnumber":"16-033","EU CT number":"2022-501017-31-00","Uuringu sponsor":"AbbVie Deutschland GmbH & Co. KG","Protokolli number":"M14-465","Uuringu nimetus":"A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)","Eriala":"reumatoloogia","Esitamise kuupäev":"4/8/16","Loa saamise kuupäev":"4/20/16"},{"Ravimiameti referentsnumber":"16-069","EU CT number":"2023-505699-31-00","Uuringu sponsor":"AbbVie Deutschland GmbH & Co. KG","Protokolli number":"M14-533","Uuringu nimetus":"A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC).","Eriala":"gastroenteroloogia","Esitamise kuupäev":"10/3/16","Loa saamise kuupäev":"10/14/16"},{"Ravimiameti referentsnumber":"17-044","EU CT number":"2024-511322-31-00","Uuringu sponsor":"Universitaetsklinikum Tuebingen AöR","Protokolli number":"2016-000222-19","Uuringu nimetus":"Effect of ALlopurinol in addition to hypothermia for hypoxicischemic Brain Injury on Neurocognitive Outcome","Eriala":"neonatoloogia","Esitamise kuupäev":"9/21/17","Loa saamise kuupäev":"1/17/18"},{"Ravimiameti referentsnumber":"18-041","EU CT number":"2023-505495-30-00","Uuringu sponsor":"Travere Therapeutics Inc.","Protokolli number":"021IGAN17001","Uuringu nimetus":"A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)","Eriala":"nefroloogia","Esitamise kuupäev":"7/27/18","Loa saamise kuupäev":"9/5/18"},{"Ravimiameti referentsnumber":"18-061","EU CT number":"2023-505478-14-00","Uuringu sponsor":"AbbVie Deutschland GmbH & Co. KG","Protokolli number":"M16-011","Uuringu nimetus":"A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)","Eriala":"reumatoloogia","Esitamise kuupäev":"11/9/18","Loa saamise kuupäev":"11/19/18"},{"Ravimiameti referentsnumber":"18-062","EU CT number":"2023-505477-33-00","Uuringu sponsor":"AbbVie Deutschland GmbH & Co. KG","Protokolli number":"M15-998","Uuringu nimetus":"A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies)","Eriala":"reumatoloogia","Esitamise kuupäev":"11/16/18","Loa saamise kuupäev":"11/22/18"},{"Ravimiameti referentsnumber":"19-006","EU CT number":"2023-507906-15-00","Uuringu sponsor":"Novartis Pharma AG","Protokolli number":"COMB157G2399","Uuringu nimetus":"An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)","Eriala":"neuroloogia","Esitamise kuupäev":"1/28/19","Loa saamise kuupäev":"2/25/19"},{"Ravimiameti referentsnumber":"19-036","EU CT number":"2022-502832-37-00","Uuringu sponsor":"Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting","Protokolli number":"HO150","Uuringu nimetus":"A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.","Eriala":"hematoloogia","Esitamise kuupäev":"8/19/19","Loa saamise kuupäev":"11/12/19"},{"Ravimiameti referentsnumber":"19-039","EU CT number":"2024-515156-21-00","Uuringu sponsor":"Arena Pharmaceuticals Inc.","Protokolli number":"APD334-303","Uuringu nimetus":"C5041012 (APD334-303) - An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis","Eriala":"gastroenteroloogia","Esitamise kuupäev":"9/11/19","Loa saamise kuupäev":"9/23/19"},{"Ravimiameti referentsnumber":"19-043","EU CT number":"2024-513762-18-00","Uuringu sponsor":"Intercept Pharmaceuticals Inc.","Protokolli number":"747-213","Uuringu nimetus":"A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid","Eriala":"gastroenteroloogia","Esitamise kuupäev":"10/17/19","Loa saamise kuupäev":"11/18/19"},{"Ravimiameti referentsnumber":"19-049","EU CT number":"2022-501531-16-00","Uuringu sponsor":"Merck Sharp & Dohme LLC","Protokolli number":"MK-3475-975","Uuringu nimetus":"A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)","Eriala":"neuroloogia","Esitamise kuupäev":"11/6/19","Loa saamise kuupäev":"12/20/19"},{"Ravimiameti referentsnumber":"19-053","EU CT number":"2022-501050-11-01","Uuringu sponsor":"Karolinska University Hospital","Protokolli number":"ALLTogether1","Uuringu nimetus":"ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)","Eriala":"hematoloogia","Esitamise kuupäev":"11/19/19","Loa saamise kuupäev":"5/13/20"},{"Ravimiameti referentsnumber":"19-062","EU CT number":"2023-503500-87-00","Uuringu sponsor":"Merck Sharp & Dohme LLC","Protokolli number":"MK-3475-992","Uuringu nimetus":"A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)","Eriala":"onkoloogia","Esitamise kuupäev":"12/13/19","Loa saamise kuupäev":"1/21/20"},{"Ravimiameti referentsnumber":"19-065","EU CT number":"2022-502640-12-01","Uuringu sponsor":"Oslo University Hospital Hf","Protokolli number":"DART","Uuringu nimetus":"DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTh (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients","Eriala":"onkoloogia","Esitamise kuupäev":"12/27/19","Loa saamise kuupäev":"4/7/20"},{"Ravimiameti referentsnumber":"20-011","EU CT number":"2023-503591-25-00","Uuringu sponsor":"Merck Sharp & Dohme LLC","Protokolli number":"MK-7339-012","Uuringu nimetus":"A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)","Eriala":"onkoloogia","Esitamise kuupäev":"4/3/20","Loa saamise kuupäev":"5/6/20"},{"Ravimiameti referentsnumber":"20-013","EU CT number":"2023-503673-38-00","Uuringu sponsor":"Amgen Inc.","Protokolli number":"20170625","Uuringu nimetus":"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke","Eriala":"kardiovaskulaarhaigused","Esitamise kuupäev":"4/9/20","Loa saamise kuupäev":"5/6/20"},{"Ravimiameti referentsnumber":"20-019","EU CT number":"2022-502746-27-00","Uuringu sponsor":"AstraZeneca AB","Protokolli number":"D9311C00001","Uuringu nimetus":"A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)","Eriala":"onkoloogia","Esitamise kuupäev":"5/18/20","Loa saamise kuupäev":"5/26/20"},{"Ravimiameti referentsnumber":"20-022","EU CT number":"2024-514404-13-00","Uuringu sponsor":"Galderma S.A.","Protokolli number":"RD.06.SPR.118163","Uuringu nimetus":"A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis","Eriala":"dermatoloogia","Esitamise kuupäev":"5/29/20","Loa saamise kuupäev":"6/29/20"}],"metadata":{"total":118,"mimetype":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"}}